OSR (NASDAQ:OSRH) Announces Earnings Results

OSR (NASDAQ:OSRH) posted its earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, FiscalAI reports. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%. The firm had revenue of $0.32 million during the quarter.

OSR Trading Up 11.7%

OSR stock opened at $0.32 on Friday. The firm has a 50 day moving average of $0.39 and a 200 day moving average of $0.47. The firm has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.85 and a beta of 0.56. OSR has a 12-month low of $0.25 and a 12-month high of $1.24.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new stake in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OSRH shares. Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.